Emverm costs so much because a single company controls the only mebendazole product available in the United States, and no generic competitors exist to drive the price down. A six-tablet supply of Emverm 100mg carries a retail price of roughly $5,387, and even with discount coupons the cost hovers around $4,288. That pricing has nothing to do with manufacturing complexity or the drug’s ingredients. It’s the result of a small market, strategic acquisitions, and a regulatory environment that allows it.
How a Cheap Generic Became a $400 Pill
Mebendazole was developed in the 1970s and spent decades as an inexpensive generic drug in the US. A single pill cost about $16 as recently as 2010. Then the generic version disappeared from the market in 2011, leaving no mebendazole product available at all.
A company called Amedra Pharmaceuticals purchased the rights to both mebendazole and albendazole (the only two prescription antiparasitic drugs commonly used for pinworms and similar infections). That gave one company a monopoly over the entire category. Amedra was later acquired by Impax Laboratories in 2015, and by January 2016 Impax launched a reformulated chewable tablet under the brand name Emverm, pricing it at around $400 per pill. That price has continued climbing. Today, the per-pill cost works out to roughly $700 or more at full retail for a six-tablet supply. The same pattern played out with albendazole (brand name Albenza), which jumped from $6 per pill in 2010 to $190 per pill after the same series of acquisitions.
Why No Competitors Have Entered
The obvious question is why another manufacturer hasn’t stepped in to sell a cheaper version. Several factors keep competitors out. Pinworm infections, while common, are a relatively small market. Most cases need only a single dose repeated once, so any generic company entering this space would be competing for a limited number of prescriptions each year. The cost of obtaining FDA approval for a generic, building a manufacturing line, and navigating the regulatory process may not look worthwhile when the total market is small.
Mebendazole also has a genuine manufacturing wrinkle. The drug exists in three different crystal forms, called polymorphs, and only one of them (polymorph C) works properly in the body. The other forms either dissolve poorly or lack therapeutic effect. If the wrong crystal form makes up too much of the final product, the pill won’t treat the infection. Manufacturers need careful quality control to ensure the correct polymorph dominates the formulation. This isn’t an insurmountable barrier, but it adds a layer of complexity that further discourages generic entry into an already small market.
What the Same Drug Costs Elsewhere
The US price becomes especially striking when you look at what mebendazole costs in other countries. In the UK and Australia, the same drug sells for about $4 to $6 per pill. In low-income countries, where mebendazole is used in mass deworming programs, it costs between one and six cents per pill. The World Health Organization lists mebendazole as an essential medicine, recognizing it as a basic, necessary drug that should be widely accessible.
The difference isn’t about the drug itself. It’s about how the US pharmaceutical market works. Other countries use government price negotiations or reference pricing systems to keep costs in check. The US generally does not regulate drug prices for brand-name products, so a company with no competitors can set whatever price the market will bear.
The Business Strategy Behind the Price
What happened with Emverm follows a well-documented pattern in the US pharmaceutical industry. A company acquires the rights to an old, off-patent drug that has few or no competitors. It then relaunches the drug (sometimes with minor reformulation, like making it chewable) under a new brand name at a dramatically higher price. Because the drug treats a condition with no good alternatives, patients and insurers have little choice but to pay.
This strategy works especially well with antiparasitic drugs because the market is small enough that generic manufacturers see little financial incentive to compete, yet large enough to generate significant revenue for a single seller charging premium prices. Amneal Pharmaceuticals, which now owns the Emverm brand after merging with Impax, faces essentially no price pressure from competitors.
Options for Reducing Your Cost
If you’ve been prescribed Emverm and are facing the full retail price, a few options exist. Amneal Pharmaceuticals offers a copay savings program for Emverm, though the company does not publicly list the specific discount amounts or eligibility requirements on its website. Pharmacy discount tools like GoodRx can reduce the cost to around $4,288 for a six-tablet supply, which is still substantial but represents savings of over $1,000 off the retail price.
For pinworm infections specifically, there is an over-the-counter alternative worth knowing about. Pyrantel pamoate (sold under brand names like Reese’s Pinworm Medicine) treats pinworms without a prescription and typically costs under $15. It works through a different mechanism than mebendazole but is effective for the most common reason people get prescribed Emverm. If your prescription is specifically for pinworms rather than another type of parasitic infection, asking your doctor about this OTC option could save you thousands of dollars.
For infections that specifically require mebendazole or albendazole, such as certain roundworm, hookworm, or whipworm infections, the options are more limited. Some compounding pharmacies may be able to prepare mebendazole at a lower cost, though availability varies. Your insurance plan’s formulary and prior authorization process will also affect what you ultimately pay out of pocket.